483
Catalent CTS, LLCFDA 483 - Catalent CTS, LLC - November 10, 2014
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Catalent CTS (Kansas City), LLC identified significant deficiencies in the manufacturing and control of Lomitapide capsules. The firm failed to adequately validate analytical methods, establish proper control procedures for wet granulation, and maintain complete master batch records. Additionally, the company did not thoroughly investigate out-of-trend results, indicating a lack of robust quality oversight.
Open in Dashboard
ID · 5793ba1a-48e1-44ab-9e6e-522ce99e4293